BioCentury | Mar 2, 2019
Product Development

Roche broadens its BD scope

...unpartnered and include two Phase I/II gene therapy candidates, SPK-8011 to treat hemophilia A and SPK-7001...
BioCentury | Mar 1, 2019
Company News

Spark gives Roche beachhead in gene therapy

...to treat hemophilia A with or without Factor VIII inhibitors. Spark's other clinical program is SPK-7001...
BioCentury | Feb 25, 2019
Company News

Spark gives Roche beachhead in gene therapy

...to treat hemophilia A with or without Factor VIII inhibitors. Spark's other clinical program is SPK-7001...
BioCentury | Feb 2, 2015
Clinical News

SPK-CHM: Phase I/II started

...began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate 2 single doses of subretinal SPK-CHM...
...inherited disorder that leads to blindness. Spark Therapeutics Inc. , Philadelphia, Pa. Product: SPK-CHM ( AAV2-hCHM...
Items per page:
1 - 4 of 4